Undisclosed GBA1 gene therapy / Voyager, Neurocrine - LARVOL DELTA

Anticipated Upcoming Milestones (GlobeNewswire) - "(i) 2025-2026: Potentially informative data read-outs expected for tau-targeting agents from multiple third parties; (ii) 2026: U.S. IND/Canadian CTA submissions + clinical trial initiation anticipated for VY1706 in AD; (iii) 2026: Neurocrine indicates potential clinical trial initiations for FA and GBA1 programs; (iv) H2 2026: Initial tau PET imaging data expected in MAD clinical trial of VY7523 in AD."

Clinical data • New trial • Alzheimer's Disease • Friedreich ataxia

Second Quarter 2025 and Recent Highlights (GlobeNewswire) - "VY7523 (anti-tau antibody): initial tau positron emission tomography (PET) data from clinical trial in Alzheimer’s disease (AD) patients expected in the second half of 2026...Potential for data from multiple gene therapy programs: Neurocrine-partnered FA and GBA1 programs anticipated to enter clinical trials in 2026; VY1706 tau silencing gene therapy anticipated to enter a clinical trial in 2026; Critical third-party data from large Phase 2 studies of an anti-tau antibody and tau knockdown program expected in 2026, which have the potential to further validate tau as a target....VY1706 (tau silencing gene therapy): IND-enabling work is underway to support an IND and clinical trial initiation expected in 2026."

Clinical data • IND • New trial • Alzheimer's Disease • Friedreich ataxia

Voyager Therapeutics Reports Third Quarter 2023 Financial and Operating Results (GlobeNewswire) - "VY-TAU01 anti-tau antibody program for Alzheimer’s disease: Voyager expects to file an IND in the first half of 2024. SOD1 gene therapy program for amyotrophic lateral sclerosis (ALS): Voyager expects to identify a lead development candidate in 2023 to support an IND in mid-2025. Voyager and Neurocrine Biosciences collaboration: Voyager and Neurocrine Biosciences continue to collaboratively advance the GBA1 gene therapy program for Parkinson’s disease and other GBA1-mediated diseases, as well as the FXN gene therapy program for Friedreich’s Ataxia."

IND • Licensing / partnership • Pipeline update • Alzheimer's Disease • Amyotrophic Lateral Sclerosis • CNS Disorders • Parkinson's Disease

Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Development and Commercialization of Voyager’s GBA1 Program and Other Next-Generation Gene Therapies for Neurological Diseases (GlobeNewswire) - "Neurocrine Biosciences, Inc...and Voyager Therapeutics, Inc...today announced the formation of a new strategic collaboration to advance multiple gene therapies for the treatment of neurological diseases. The collaboration includes Voyager’s preclinical, intravenously administered GBA1 gene therapy program for Parkinson’s disease and other GBA1-mediated diseases, which combines a GBA1 gene replacement payload with novel capsids from Voyager’s TRACERTM (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) platform....Under the terms of the agreement, Neurocrine Biosciences has agreed to pay Voyager $175 million up front..."

Licensing / partnership